Drug intelligence / Profile preview

Atrocal-XT

Development stage: Unknown
Lead developer: Atro Pharma
Modality: Small Molecules
Administration: Oral

Overview

Atrocal-XT is a nutraceutical supplement developed by Atro Pharma, primarily indicated for bone health and maintenance. Formulated as an oral tablet, it contains a combination of Calcium (500mg), Vitamin D3 (2000IU), and a B-vitamin complex consisting of L-Methylfolate (1mg), Methylcobalamin (1500mcg), and Pyridoxal 5-Phosphate (20mg). The product supports bone mineral density through calcium and vitamin D3 supplementation while the B-vitamins aid in nerve function and homocysteine regulation. It is currently approved and marketed in India.

Brand names: Atrocal-XT

Targets

VDR (Vitamin D receptor)

Beyond the preview

Go deeper on Atrocal-XT.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Atrocal-XT.

Explore the full profile